Effects of upadacitinib or adalimumab on pain in rheumatoid arthritis and psoriatic arthritis: results from randomised phase 3 studies.
Peter C Taylor, Arthur Kavanaugh, Louis Bessette, Bruno Fautrel, Tsutomu Takeuchi, Andrew Garrison, Tianming Gao, Ralph Lippe, Diane Caballero, Charles Phillips, Philip J Mease
INTRODUCTION: Patients with rheumatoid (RA) or psoriatic (PsA) arthritis can experience debilitating pain.
METHODS: Post hoc analyses of phase 3, double-blind studies in patients with active disease despite treatment (SELECT-COMPARE, SELECT-PsA 1) assessed the effects of upadacitinib or adalimumab versus placebo on pain in patients with attenuation of inflammation (AoI) versus remaining inflammation at weeks 12 and 24/26 (PsA/RA). Further, a mediation analysis assessed the direct/indirect effect of treatment on pain using the Patient's Global Assessment of pain (PtGA) and 28 tender joint count (TJC28) at weeks 2/12/26 in RA, and weeks 16/24 in PsA.
RESULTS: In patients with RA+AoI, PtGA scores improved more with upadacitinib (least squares mean change, -42.9) versus adalimumab (-34.7 (p<0.05)) or placebo (-33.1 (p<0.05)) at week 12 from baseline; improvements were similar across groups by week 26. For PsA+AoI, improvement was greater with upadacitinib (week 12, -2.7; week 24, -3.8) versus placebo (-1.8 (p<0.05); -2.8 (p<0.001), respectively) and similar to adalimumab (-2.8, -3.6). For RA, the direct effect on pain was nearly two times greater with upadacitinib versus placebo compared with adalimumab at weeks 12/26. For PsA, total effects on pain (TJC28 improvement) at weeks 16/24 were greater with upadacitinib (2.16 and 2.30) and adalimumab (1.35 and 1.71) versus placebo.
CONCLUSIONS: Upadacitinib effectively reduced pain in active RA and PsA, including in patients with AoI. The greater pain relief observed in RA with upadacitinib versus adalimumab might indicate both direct (relieving non-inflammatory pain) and indirect (suppressing inflammation) effects.
KM 提取结果
0 个 Figure · 0 个 KM 面板
尚未提取到 KM 面板。其他 Figure(6,默认折叠)
这些图片未产生 KM 曲线结果,不在主页面重复展示。
Figure 1Figure 1. Multiple mediator analysis for RA ( A ) and PsA ( B ) studies. Change in pain was measured by PtGA of pain or TJC28. CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; LEI, Leeds Enthesitis Index; PsA, psoriatic arthritis; PtGA, Patient’s Global Assessment; RA, rheumatoid arthritis; SJC28, swollen joint count based on 28 joints; TJC28, tender joint count based on 28 joints.
非 KM Figure
Figure 2Figure 2. LS mean change from baseline to weeks 12 and 24/26 in PtGA of pain and LS mean pain score by visit at weeks 12 and 24/26 among patients with RA ( A, B, C, D ) or PsA ( E, F, G, H ) who had attenuation of inflammation or remaining inflammation. Attenuation of inflammation was defined as SJC66 of 0 and CRP<6 mg/L. ADA, adalimumab; BL, baseline; CRP, C-reactive protein; EOW, every other week; LS, least squares; PBO, placebo; PsA, psoriatic arthritis; PtGA, Patient’s Global Assessment; QD, one time per day; RA, rheumatoid arthritis; SJC66, swollen joint count based on 66 joints; UPA, upadacitinib.
非 KM Figure
Figure 3Figure 3. Absolute mean PtGA of pain at weeks 12 and 24/26 among patients with RA ( A, B ) or PsA ( C, D ) who had attenuation of inflammation or remaining inflammation. Attenuation of inflammation was defined as SJC66 of 0 and CRP<6 mg/L. ADA, adalimumab; CRP, C-reactive protein; EOW, every other week; PBO, placebo; PsA, psoriatic arthritis; PtGA, Patient’s Global Assessment; QD, one time per day; RA, rheumatoid arthritis; SJC66, swollen joint count based on 66 joints; UPA, upadacitinib.
非 KM Figure
Figure 4Figure 4. ≥30%, ≥50% or ≥70% reduction in pain from baseline among patients with attenuation of inflammation or remaining inflammation at week 12 in RA ( A ) and PsA ( B ) population. ADA, adalimumab; EOW, every other week; PBO, placebo; PsA, psoriatic arthritis; QD, one time per day; RA, rheumatoid arthritis; UPA, upadacitinib.
非 KM Figure
Figure 5Figure 5. Direct effect and indirect effect of treatment on pain assessed as improvement in PtGA of pain at weeks 2, 12 and 26 in RA ( A ) and at weeks 16 and 24 in PsA ( B ). Panel A: weeks 2 and 12 data are observed case analyses; week 26 data are LOCF analyses. Panel B: week 16 data are observed case analyses; week 24 data are LOCF analyses. Mediation analyses were conducted using the methods of Preacher and Hayes. Estimates for the following effects were generated, controlling for baseline value of PtGA of pain: direct effect of treatment on the outcome of improvement from baseline in PtGA of pain (ie, total treatment effect not accounted for by indirect effects), indirect effects of treatment on the outcome via mediators of change from baseline in ESR/SJC28/CRP (RA) or itch/CRP/total enthesitis/LEI (PsA), and total effect of treatment on the outcome. *UPA vs PBO or ADA vs PBO; p<0.001. ADA, adalimumab; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; LEI, Leeds Enthesitis Index; LOCF, last observation carried forward; PBO, placebo; PsA, psoriatic arthritis; PtGA, Patient’s Global Assessment; RA, rheumatoid arthritis; SJC28, swollen joint count based on 28 joints; UPA, upadacitinib.
非 KM Figure
Figure 6Figure 6. Direct effect and indirect effect of treatment on pain assessed as improvement in TJC28 at weeks 2, 12 and 26 in RA ( A ) and at weeks 16 and 24 in PsA ( B ). Panel A: weeks 2 and 12 data are observed case analyses; week 26 data are LOCF analyses. Panel B: week 16 data are observed case analysis; week 24 data are LOCF analyses. Mediation analyses were conducted using the methods of Preacher and Hayes. Estimates for the following effects were generated, controlling for baseline value of PtGA of pain: direct effect of treatment on the outcome of improvement from baseline in TJC28 (ie, total treatment effect not accounted for by indirect effects), indirect effects of treatment on the outcome via mediators of change from baseline in ESR/SJC28/CRP (RA) or itch/CRP/total enthesitis/LEI (PsA) and total effect of treatment on the outcome. *UPA vs PBO or ADA vs placebo; p<0.001. † ADA vs PBO; p<0.05. ADA, adalimumab; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; LEI, Leeds Enthesitis Index; LOCF, last observation carried forward; PBO, placebo; PsA, psoriatic arthritis; PtGA, Patient’s Global Assessment; RA, rheumatoid arthritis; SJC28, swollen joint count based on 28 joints; TJC28, tender joint count based on 28 joints; UPA, upadacitinib.